GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research

NEXT STORY
Orgenesis Announces Anti-Viral “BioShield” Program Designed to Potentially Increase Preparedness, Rapidly Address Virus Spread and Protect Against Future Outbreaks such as COVID-19
PREV STORY
Press Release Oncology Venture is issuing 2,255,639 shares under its convertible note agreement with Negma Group LTD and Park Partners GB
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Alberta Project Explores Use of Synthetic Data as Alternative to Health Data Utilization

author_avatar
NASDAQ Market News

Loxo Oncology Announces the Closing of its Follow-On Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

STAMFORD, Conn., Jan. 10, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical ...

author_avatar
NASDAQ Market News

Preclinical Data for Kura Oncology Development Compounds to be Presented at AACR Annual Meeting 2017

LA JOLLA, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a ...

author_avatar
NASDAQ Market News